STATEMENT OF NEED

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm of the synovium, bursae, and tendon sheaths that can lead to chronic pain, recurrent joint swelling, progressive functional impairment, and irreversible joint destruction. Localized TGCT can often be effectively managed with surgical excision; however, diffuse TGCT is associated with a substantial risk of recurrence after surgery. Recent advances have led to the approval of systemic therapies targeting the CSF-1/CSF1R signaling pathway for patients with symptomatic TGCT that is not amenable to surgery. These CSF1R inhibitors have demonstrated meaningful improvements in tumor response, range of motion, physical function, and patient-reported outcomes. To individualize treatment decisions in a rapidly changing therapeutic landscape, clinicians must navigate important differences in toxicity profiles and monitoring requirements to optimize long-term outcomes (Stacchiotti et al, 2023; Assi et al, 2025). In this Virtual Tumor Board activity, Brian E. Brigman, MD, PhD; Jason L. Hornick, MD, PhD; Robert A. Lefkowitz, MD; and Richard F. Riedel, MD, explore interprofessional strategies to equip the multidisciplinary team to accurately diagnose localized and diffuse TGCT, integrate evolving consensus recommendations, and individualize treatment decisions for enhanced outcomes in TGCT. 

TARGET AUDIENCE

Medical oncologists, orthopedic oncologists, pathologists, radiologists, advanced practice providers, and other health care providers (HCPs) involved in the management of patients with tenosynovial giant cell tumor (TGCT).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

• Identify clinical, pathologic, and radiologic features of localized and diffuse TGCT to support a timely and accurate diagnosis

• Apply current evidence and expert guidance to select appropriate treatment strategies for patients with TGCT

• Implement risk mitigation and monitoring strategies to reduce complications associated with systemic therapies for TGCT

• Recognize and manage common and serious CSF1R inhibitor–related adverse events

REGISTRATION

There is no fee to participate in or claim CME/AAPA credit for this activity.

PROVIDED BY

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 7/13/27. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development

A maximum of 1.25 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Brian E. Brigman, MD, PhD, discloses that he has served on an advisory board or panel for Daiichi Sankyo, Deciphera, and Musculoskeletal Transplant Foundation; and that he has received grants/research support from Musculoskeletal Transplant Foundation.

Jason L. Hornick, MD, PhD, has no relevant financial relationships to disclose.

Robert Lefkowitz, MD, has no relevant financial relationships to disclose.

Richard F. Riedel, MD, discloses that he has served on an advisory board or panel for AADi, Adaptimmune, Bayer, Blueprint, Boehringer Ingelheim, Cogent, Daiichi Sankyo, Deciphera, EMD Serono, GlaxoSmithKline, Ipsen, NanoCarrier, Recordati, Replimmune, and SpringWorks; that he has served as a consultant for GlaxoSmithKline and SpringWorks; and that he has received grants/research support from AADi, Adaptimmune, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi Sankyo, Deciphera, GlaxoSmithKline, InhibRx, Intensity Therapeutics, Kura Oncology, NanoCarrier, Oncternal, PTC Therapeutics, SARC, Servier, SpringWorks, SynOx Therapeutics, Tracon, Trillium, and US WorldMeds.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.

• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

Supported by an independent educational grant from Daiichi Sankyo.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.